- Home
- BMGL vs COEP Comparison
BMGL vs COEP Comparison
Compare BMGL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- COEP
- Stock Information
- Founded
- BMGL 2001
- COEP 2017
- Country
- BMGL Singapore
- COEP United States
- Employees
- BMGL N/A
- COEP N/A
- Industry
- BMGL
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMGL
- COEP Health Care
- Exchange
- BMGL NYSE
- COEP Nasdaq
- Market Cap
- BMGL 32.7M
- COEP 27.4M
- IPO Year
- BMGL 2025
- COEP N/A
- Fundamental
- Price
- BMGL $2.25
- COEP $9.47
- Analyst Decision
- BMGL
- COEP
- Analyst Count
- BMGL 0
- COEP 0
- Target Price
- BMGL N/A
- COEP N/A
- AVG Volume (30 Days)
- BMGL 5.2M
- COEP 38.0K
- Earning Date
- BMGL 01-01-0001
- COEP 08-15-2025
- Dividend Yield
- BMGL N/A
- COEP N/A
- EPS Growth
- BMGL N/A
- COEP N/A
- EPS
- BMGL 0.02
- COEP N/A
- Revenue
- BMGL $7,342,469.00
- COEP $62,874.00
- Revenue This Year
- BMGL N/A
- COEP N/A
- Revenue Next Year
- BMGL N/A
- COEP N/A
- P/E Ratio
- BMGL $153.47
- COEP N/A
- Revenue Growth
- BMGL 2.28
- COEP N/A
- 52 Week Low
- BMGL $0.91
- COEP $2.31
- 52 Week High
- BMGL $9.40
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- COEP 62.24
- Support Level
- BMGL N/A
- COEP $7.25
- Resistance Level
- BMGL N/A
- COEP $9.90
- Average True Range (ATR)
- BMGL 0.00
- COEP 0.63
- MACD
- BMGL 0.00
- COEP 0.26
- Stochastic Oscillator
- BMGL 0.00
- COEP 85.62
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.